EGFR and metastatic colorectal cancer: For instance, Symphogen A/S has developed Sym004, which is currently being evaluated in a clinical trial phase II as a mixture (1:1) of 2 chimeric IgG1 Abs (mAb992 and mAb1024 against nonoverlapping epitopes on EGFR to target metastatic colorectal cancer).60